Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost-Utility and Budget Impact Analysis.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
25 Jul 2024
Historique:
received: 08 07 2024
revised: 19 07 2024
accepted: 22 07 2024
medline: 1 9 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Two vaccines against rotavirus diseases, Rotarix

Identifiants

pubmed: 39205168
pii: v16081194
doi: 10.3390/v16081194
pii:
doi:

Substances chimiques

Rotavirus Vaccines 0
Vaccines, Attenuated 0
RIX4414 vaccine 0
RotaTeq 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Iñaki Imaz-Iglesia (I)

National Health School, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.

Montserrat Carmona (M)

Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.

Esther E García-Carpintero (EE)

Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.

Lucía Pedrosa-Pérez (L)

Health Technology Assessment Agency, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.

Alejandro Martínez-Portillo (A)

National Health School, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.

Enrique Alcalde-Cabero (E)

National Centre of Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III), 28029 Madrid, Spain.
Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.

Renata Linertová (R)

Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
Assessment Service of the Canary Islands Health Service (Servicio de Evaluación del Servicio Canario de Salud/SESCS), 38109 Tenerife, Spain.

Lidia García-Pérez (L)

Chronicity, Primary Healthcare and Health Promotion Research Network (Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud/RICAPPS), 28029 Madrid, Spain.
Assessment Service of the Canary Islands Health Service (Servicio de Evaluación del Servicio Canario de Salud/SESCS), 38109 Tenerife, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH